Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Alings

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
American Heart Journal|December 17, 2016
Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trialElton Dudink, Brigitte Essers, Wouter Holvoet, et al.
The New England Journal of Medicine|September 1, 2009
Dabigatran versus warfarin in patients with atrial fibrillationStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Heart Rhythm|March 17, 2024
Comparing adolescent- and adult-onset unexplained cardiac arrest: Results from the Dutch Idiopathic VF RegistryLisa M Verheul, Wiert F Hoeksema, Sanne A Groeneveld, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 18, 2021
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trialBao Oanh Nguyen, Harry J G M Crijns, Jan G P Tijssen, et al.
JACC. Clinical Electrophysiology|April 3, 2026
Implantable Cardioverter-Defibrillator Therapy and Implantable Cardioverter-Defibrillator Complications in Idiopathic Ventricular Fibrillation PatientsRozan Roodenburg, Lisa M Verheul, Wiert F Hoeksema, et al.
Circulation. Arrhythmia and Electrophysiology|November 11, 2023
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)A John Camm, Jonathan P Piccini, Marco Alings, et al.
The New England Journal of Medicine|March 17, 2010
Lenient versus strict rate control in patients with atrial fibrillationIsabelle C Van Gelder, Hessel F Groenveld, Harry J G M Crijns, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Lancet (London, England)|June 18, 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trialBruce S Stambler, A John Camm, Marco Alings, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
American Heart Journal|December 17, 2016
Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trialElton Dudink, Brigitte Essers, Wouter Holvoet, et al.
The New England Journal of Medicine|September 1, 2009
Dabigatran versus warfarin in patients with atrial fibrillationStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Heart Rhythm|March 17, 2024
Comparing adolescent- and adult-onset unexplained cardiac arrest: Results from the Dutch Idiopathic VF RegistryLisa M Verheul, Wiert F Hoeksema, Sanne A Groeneveld, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 18, 2021
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trialBao Oanh Nguyen, Harry J G M Crijns, Jan G P Tijssen, et al.
JACC. Clinical Electrophysiology|April 3, 2026
Implantable Cardioverter-Defibrillator Therapy and Implantable Cardioverter-Defibrillator Complications in Idiopathic Ventricular Fibrillation PatientsRozan Roodenburg, Lisa M Verheul, Wiert F Hoeksema, et al.
Circulation. Arrhythmia and Electrophysiology|November 11, 2023
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)A John Camm, Jonathan P Piccini, Marco Alings, et al.
The New England Journal of Medicine|March 17, 2010
Lenient versus strict rate control in patients with atrial fibrillationIsabelle C Van Gelder, Hessel F Groenveld, Harry J G M Crijns, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Lancet (London, England)|June 18, 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trialBruce S Stambler, A John Camm, Marco Alings, et al.
Pageof 13